re: Wow. Brazil Study Shows *early* HCQ significantly decreases hospitalization rates

quote:

---

Sooooo... why can't Louisiana do it? Anyone?

---

It's a non randomized, non placebo-controlled study on patients who may not even have COVID. Essentially it gives us no data on how the medicine affects COVID patients.

The placebo effect is a real thing, hence using no placebo pill in your "control" group vs only actual medicine in the treatment arm lends itself to a bias towards your treatment arm looking better than it actually is. Does that make sense?

this study is fricking terrible to extrapolate to the united states

quote:

---

The dose of hydroxychloroquine used was 1,200 mg daily for three days, followed by 800 mg daily for 2-3 weeks. This is a huge dose of hydroxychloroquine (in comparison, the most commonly used regimen in the United States currently seems to be 800 mg on the first day followed by 400 mg daily for four days).

---

no wonder they saw those side effects

the brazil study did the exact dose the US uses except for 2 days longer

I dont think youre actually in healthcare or make decisions off medical literature if you think a study that started therapy 17 days after symptoms at a highly toxic dose is the "best weve got"

Much more interested in the Galedisivir trial ongoing in Brazil.

Only as it pertains to "clinical trials in Brazil".

HCQ will get it's day in court with a placebo controlled, double blind study at some point.

quote:

---

Results This study included 181 patients with SARS-CoV-2 pneumonia; 84 received HCQ within 48 hours of admission (HCQ group) and 97 did not (no-HCQ group). Initial severity was well balanced between the groups. In the weighted analysis, 20.2% patients in the HCQ group were transferred to the ICU or died within 7 days vs 22.1% in the no-HCQ group (16 vs 21 events, relative risk [RR] 0.91, 95% CI 0.47–1.80). In the HCQ group, 2.8% of the patients died within 7 days vs 4.6% in the no-HCQ group (3 vs 4 events, RR 0.61, 95% CI 0.13–2.89), and 27.4% and 24.1%, respectively, developed acute respiratory distress syndrome within 7 days (24 vs 23 events, RR 1.14, 95% CI 0.65–2.00). Eight patients receiving HCQ (9.5%) experienced electrocardiogram modifications requiring HCQ discontinuation.

Interpretation These results do not support the use of HCQ in patients hospitalised for documented SARS- CoV-2-positive hypoxic pneumonia.

---

Medrxiv.org

But but but...trump indirectly owns 100 bucks in a mutual fund that includes a pharmaceutical company that, in addition to all the other drugs they make, makes one type of off patent hydroxychloroquine!

He stands to make dozens of dollars in profit if hxdroxychloroquine turns out to be effective! It’s obvious that he is just promoting the drug to make money. He probably plucked it out of thin air once he heard about this obscure company a mutual fund he owned invested in made it! CNN and dem governors say it doesn’t do anything and is in fact killing people because they are eating fish cleaner because Blonald Flumpf told them to!!!


REEEEEEEEEEEEE!!!!

These patients were overdosed.

quote:

---

Much more interested in the Galedisivir trial ongoing in Brazil.

---

Yeah. Sadly remdesivir also looks bunk.
LINK

I'm not sure what was the point of adding that study to this thread. The study noted in the OP was using HCQ as an early treatment in patients with no current criteria for hospitalization. The study you linked, presumably to make a statement that offset the OP study, was in hospitalized patients. It's quite common for some drugs to work at one stage of a disease but not work as well or at all in a later stage. So, both could be meaningful results and it would still be very good news.